TFF PHARMACEUTICALS, INC. (TFFP) News
Filter TFFP News Items
TFFP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TFFP News Highlights
- For TFFP, its 30 day story count is now at 3.
- Over the past 28 days, the trend for TFFP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about TFFP are DRUG, HA and MG.
Latest TFFP News From Around the Web
Below are the latest news stories about TFF Pharmaceuticals Inc that investors may wish to consider to help them evaluate TFFP as an investment opportunity.
TFF Pharma's Inhaled Niclosamide Shows Potent Activity Against Omicron VariantPreclinical studies show that TFF Pharmaceuticals Inc's (NASDAQ: TFFP) inhaled niclosamide product candidate inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2. More specifically, nirmatrelvir and molnupiravir showed complete inhibition of the Omicron variant at 2.5 μM. In the studies announced today by TFF Pharmaceuticals, inhaled niclosamide demonstrated complete inhibition of Omicron at only 1μM. These studies also confirm the previous findings, which validated th |
TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1 Safety and Pharmacokinetic Data of Inhaled Niclosamide by End of 1Q’22 AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film |
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple Variants AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it ha |
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the... |
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma PatientsFinal Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic |
TFF Pharmaceuticals Hosting Science Day on December 13, 2021AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p |
TFF Pharmaceuticals (NASDAQ:TFFP) Rating Lowered to Sell at Zacks Investment ResearchZacks Investment Research downgraded shares of TFF Pharmaceuticals (NASDAQ:TFFP) from a hold rating to a sell rating in a research report report published on Friday, Zacks.com reports. According to Zacks, TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory [] |
TFF Pharmaceuticals, Inc. (TFFP) Q3 2021 Earnings Call TranscriptWith me on the line today is Glenn Mattes, president and CEO of TFF and Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF director of clinical development; and Dr. The press release announcing our third quarter results is available on the TFF Pharmaceuticals website. |
TFF Pharmaceuticals EPS misses by $0.13, misses on revenueNo summary available. |
TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdatePositive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing |